Skip to main content
Harbin Pharmaceutical Group Co.,Ltd. logo

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 ISIN · CNE0000009T3 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,824 across all filing types
Latest filing 2022-04-11 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

https://www.hayao.com/

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
哈药集团股份有限公司关于续聘会计师事务所的补充公告
Regulatory Filings Classification · 90% confidence The document is a supplementary announcement regarding the reappointment of an accounting firm, detailing the qualifications and experience of the signing auditors and quality control reviewer. It does not contain any financial statements or audit results itself, but rather supplements a previous announcement about the reappointment. The document length is short (683 characters) and it is an announcement related to audit services rather than the audit report itself. Therefore, it fits best under Audit Report / Information (AR) as it relates to audit matters but is not a full annual report or standalone audit report. However, since it is a supplementary announcement about the audit firm appointment, it is more appropriate to classify it as Regulatory Filings (RNS) because it is an announcement and does not contain audit results or applied accounting principles. Hence, the best classification is Regulatory Filings (RNS).
2022-04-11 Chinese
哈药集团股份有限公司2021年度内部控制审计报告
Regulatory Filings
2022-04-08 Chinese
哈药集团股份有限公司关于续聘会计师事务所的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the reappointment of an accounting firm (Beijing Xinghua Certified Public Accountants) for auditing services for the year 2022. It includes details about the accounting firm, its qualifications, audit fees, and the approval process by the board and independent directors. The document does not contain actual financial statements or audit results but is a formal announcement of the intention to reappoint the auditor. The document length is under 5,000 characters and it serves as a notice rather than the audit report itself. Therefore, it fits best under the category of Regulatory Filings (RNS), which covers miscellaneous regulatory announcements that do not fit other specific categories.
2022-04-08 Chinese
哈药集团股份有限公司关于计提资产减值准备的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from 哈药集团股份有限公司 regarding the provision for asset impairment for the year 2021. It details the impairment provisions for bad debts, inventory write-downs, fixed assets, goodwill, and construction in progress. The document includes the board of directors' and independent directors' opinions, confirming the appropriateness and compliance of the impairment provisions with accounting standards. The document is relatively short (2392 characters) and is structured as a formal announcement rather than a full financial report. It does not contain comprehensive financial statements or detailed financial analysis typical of an Annual Report (10-K) or Interim Report (IR). Instead, it focuses on a specific accounting event (asset impairment provision) and its impact on the company's profit. This type of document fits best under Regulatory Filings (RNS), as it is a regulatory announcement about accounting provisions and does not constitute a full audit report or annual report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2022-04-08 Chinese
哈药集团股份有限公司董事会审计委员会2021年度履职报告
Audit Report / Information Classification · 95% confidence The document is titled as the "Board Audit Committee 2021 Annual Performance Report" of Harbin Pharmaceutical Group Co., Ltd. It details the audit committee's activities during 2021, including meetings held, evaluation of external auditors, internal audit guidance, review of financial reports, and internal control assessments. The document is a report on the audit committee's duties and performance rather than a standalone audit report or the full annual report. It does not contain full financial statements or detailed audit results but summarizes the committee's oversight and evaluations. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and related information excluding full annual reports. The document length is 2431 characters, which is sufficient for a detailed committee report but not a full annual report. Therefore, the classification is AR with high confidence. FY 2021
2022-04-08 Chinese
哈药集团股份有限公司2021年年度报告_摘要
Annual Report Classification · 95% confidence The document is titled as the "2021 年年度报告摘要" which translates to "2021 Annual Report Summary". It contains detailed financial data for the year 2021, including main accounting data and financial indicators over three years, quarterly financial data, shareholder information, business overview, and management discussion of business conditions. The document includes audited financial results and comprehensive company information typical of an annual report. The length of the document (7035 characters) and the detailed financial and operational data confirm it is the actual annual report summary, not just an announcement or a brief. Therefore, the document fits the definition of an Annual Report (10-K). FY 2021
2022-04-08 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.